Temozolomide and Pituitary Tumors : Current Understanding, Unresolved Issues, and Future Directions

ABSTRACT: Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-year progression-free survival in both aggressive pituitary adenomas and pituitary carcinomas. In this paper, we review the mechanism of action of temozolomide as alkylating agent, its interaction with deoxyribonucleic acid repair systems, therapeutic effects in pituitary tumors, unresolved issues, and future directions relating to new possibilities of targeted therapy.

• Autores: Syro Moreno, Luis Vicente; Rotondo, Fabio; Camargo Guerrero, Mauricio; Ortíz Gómez, León Darío; Serna Ortíz, Carlos Andrés; Kovacs, Kalman
• Tipo de recurso: Review article
• Fecha de publicación: 2018
• Institución: Universidad de Antioquia
• Repositorio: Repositorio UdeA
• Idioma: eng
• OAI Identifier: oai:bibliotecadigital.udea.edu.co:10495/20366
• Acceso en línea: http://hdl.handle.net/10495/20366; https://www.frontiersin.org/articles/10.3389/fendo.2018.00318/full
• Palabra clave: Agentes alquilantes; Alkylating Agents; Antineoplastic Agents; Antineoplásicos; Reparación del ADN; DNA Repair; Neoplasias; Neoplasms; Tumores Neuroendocrinos; Neuroendocrine Tumors; O(6)-Methylguanine-DNA Methyltransferase; O(6)-Metilguanina-ADN Metiltransferasa; Neoplasias Hipofisarias; Pituitary Neoplasms; Temozolomida; Temozolomide; Metiltransferasa; Methyltransferases; Quimioterapia; Chemotherapy
• Rights: openAccess
• License: http://creativecommons.org/licenses/by/2.5/co/